Eisai dials back forecasts for Alzheimer's drug Leqembi | pharmaphorum
https://pharmaphorum.com/news/eisai-dials-back-forecasts-alzheimers-drug-leqembi
Eisai has retreated from the optimistic view of sales growth for Alzheimer's disease drug Leqembi it held earlier this year as uptake remains sluggish.
In its six-month financial report for the current fiscal year published this morning, the Japanese drugmaker revealed Leqembi (lecanemab) sales came in at JPY 16.3 billion (around $107 million), of which around JPY 10.5 billion came from the US.
That has prompted the company to reduce its fiscal 2024/25 projections for the drug to JPY 42.5 billion ($279 million) from JPY 56.5 billion in May, after an encouraging start to the year.
So far, the Biogen-partnered drug has been launched in the US, Japan, China, Hong Kong, Israel, UAE, and GB, and approved in South Korea. Prospects for the drug were, however, recently dashed after regulators in the EU and Australia indicated they were not minded to approve the drug because its efficacy did not outweigh the risk of side effects.
Meanwhile, recent reimbursement decisions have not gone in Eisai's favour. NICE, the health technology assessment (HTA) agency for England and Wales recently rejected NHS coverage of the drug, in part because of the costs associated with delivering it and monitoring for side effects.
https://pharmaphorum.com/news/eisai-dials-back-forecasts-alzheimers-drug-leqembi
Eisai has retreated from the optimistic view of sales growth for Alzheimer's disease drug Leqembi it held earlier this year as uptake remains sluggish.
In its six-month financial report for the current fiscal year published this morning, the Japanese drugmaker revealed Leqembi (lecanemab) sales came in at JPY 16.3 billion (around $107 million), of which around JPY 10.5 billion came from the US.
That has prompted the company to reduce its fiscal 2024/25 projections for the drug to JPY 42.5 billion ($279 million) from JPY 56.5 billion in May, after an encouraging start to the year.
So far, the Biogen-partnered drug has been launched in the US, Japan, China, Hong Kong, Israel, UAE, and GB, and approved in South Korea. Prospects for the drug were, however, recently dashed after regulators in the EU and Australia indicated they were not minded to approve the drug because its efficacy did not outweigh the risk of side effects.
Meanwhile, recent reimbursement decisions have not gone in Eisai's favour. NICE, the health technology assessment (HTA) agency for England and Wales recently rejected NHS coverage of the drug, in part because of the costs associated with delivering it and monitoring for side effects.